Losartan/Chlorthalidone in fixed dose

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Essential Arterial Hypertension

Drug Information

Target Indication

Essential Arterial Hypertension

Clinical Trial

Last updated: 1/27/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

LRVIY

Laboratorios Farmaceuticos Rovi, S.A./ADR

Related Pipeline

Allergic Rhinoconjunctivitis

Osteoarthritis of Knee

Alopecia

Influenza, Human

Arterial Hypertension